Skip Navigation



NDT Advance Access published online on May 31, 2005
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfh915
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/9/1889    most recent
gfh915v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Attman, P.-O.
Right arrow Articles by Fager, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Attman, P.-O.
Right arrow Articles by Fager, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org
Received December 15, 2004
Accepted April 22, 2005

Original Articles

Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia

Per-Ola Attman 1*, Pia Ottosson 1, Ola Samuelsson 1, Ulf G. Eriksson 2, Maria Eriksson-Lepkowska 2, and Gunnar Fager 2

1 Department of Nephrology, Sahlgrenska University Hospital, Göteborg, Sweden
2 AstraZeneca R&D, Mölndal, Sweden

* To whom correspondence should be addressed.
Per-Ola Attman, E-mail: per-ola.attman{at}vgregion.se



  Abstract

Background. This study assessed the feasibility of replacing intravenous (i.v.) dalteparin with the direct thrombin inhibitor (DTI) melagatran administered via dialysis fluid in patients undergoing haemodialysis, and also examined the pharmacokinetics of melagatran with and without dialysis.

Methods. During two 4 h haemodialysis sessions, 10 adult patients were administered i.v. dalteparin. During two subsequent sessions, melagatran was administered as an i.v. bolus before dialysis, and in the dialysis fluid. The pharmacokinetics of melagatran administered as a bolus before dialysis, and of i.v. melagatran during a dialysis-free day, were studied. Dialysis performances were evaluated from clinical criteria including clot formation in the dialyzer and bloodlines, pre-post dialyzer pressures and iohexol clearance. Anticoagulant efficacy was evaluated from dialysis success.

Results. All dialysis sessions were successful, with no apparent difference in clot formation between the two treatments. Median iohexol clearance was similar with dalteparin (99-103 ml/min) and melagatran in the dialysis fluid (98-100 ml/min). There was no difference in pre- and post-dialyzer bloodline pressures between the two treatments. During dialysis sessions with melagatran in dialysis fluid, melagatran concentrations in plasma rapidly equilibrated to 70% of those in dialysis fluid. While the clearance of melagatran was low in patients with renal failure (mean±SD, 0.93±0.36 l/h), haemodialysis provided efficient clearance of melagatran (7.20±0.76 l/h). Melagatran clearance by dialysis (104±10 ml/min) was comparable to iohexol clearance.

Conclusions. The DTI melagatran administered via dialysis fluid may provide sufficient anticoagulation for haemodialysis. Melagatran is rapidly cleared from plasma by haemodialysis, suggesting that this method may be used to decrease drug levels in patients with renal impairment.

Keywords: anticoagulant; chronic uraemia; haemodialysis; melagatran; thrombosis; ximelagatran.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.